FSD Pharma Inc. HUGE Archives - Page 2 of 2

MondayApr 22, 2024 11:11 am

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) today provided an update by way of a news release issued by Celly Nutrition Corp. (“Celly Nu”), and its launching of unbuzzd(TM), an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body’s natural processes for metabolizing alcohol and promoting alertness. According to the announcement, on April 22, 2024, Celly Nu announced a strategic partnership with BevSource, a St. Paul, Minnesota-based leading provider of beverage development, production and operations solutions. The partnership will assist with the production and distribution process of…

WednesdayApr 17, 2024 2:46 pm

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Expansion of Investigative Pipeline

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions. The company today announced the expansion of its pipeline into metabolic and related disorders including weight loss and liver health. FSD Pharma has initiated investigations into certain ingredients and combinations of ingredients that show promise in improving liver health, reducing metabolic disease and reducing visceral fat. The company is leading these efforts to potentially create a new exciting product line in addition to unbuzzd(TM). To view the full press release, visit https://ibn.fm/mpMNa About FSD Pharma Inc. FSD is…

WednesdayMar 27, 2024 1:03 pm

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, through its subsidiary, HUGE Biopharma Australia Pty Ltd., entered into agreement with iNGENu CRO Pty Ltd. The agreement outlines plans to conduct a phase 1 study. The randomized, double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants. A patented new chemical entity, Lucid-21-302 is a first-in-class, nonimmunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis…

TuesdayMar 15, 2022 11:19 am

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in Recent EIO Report from Crystal Research Associates

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced the release of an executive informational overview(R) (“EIO”) from Crystal Research Associates LLC. The 58-page report reviews FSD Pharma’s drug-development pipeline and operational milestones. Crystal Research Associates has created a reputation for successfully reporting on small- and mid-cap companies to investors; the company has released previous reports on FSD Pharma’s performance. The most recent report features FSD’ Pharma’s major milestones, drug pipeline and overall operations. To view the full report, visit https://ibn.fm/dpUnE To view the full…

TuesdayJan 18, 2022 11:47 am

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Member Named to the Order of Canada

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has announced that a member of its Research and Clinical Advisory Board has been appointed to the Order of Canada. According to the announcement, Eleanor N. Fish, PhD, was named a Member of the Order for her contributions to immunology, particularly her groundbreaking research regarding the use of interferon-alpha in the treatment of disease. The Order of Canada is among Canada’s highest civilian honors and recognizes individuals whose service shapes society and whose compassion unites communities. Appointments…

TuesdayJan 04, 2022 1:33 pm

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life-sciences holding company dedicated to building a portfolio of assets and biotech solutions, will be involved in this month’s H.C. Wainwright Bioconnect Conference. The three-day conference is scheduled for Jan. 10–13, 2022. FSD Pharma interim CEO Anthony Durkacz will present at the conference; his presentation is scheduled for release on Jan. 10, 2022, at 7 a.m. ET, and will be available for conference attendees. Durkacz will also be available for one-on-one meetings with conference participants. To view the conference, visit https://ibn.fm/dqhxw To view the full press release, visit https://ibn.fm/411fV About FSD…

Site Search

Company Search

Tag: FSD Pharma Inc. HUGE

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Issues Update on Celly Nu’s Pending Launch of unbuzzd(TM)

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Announces Expansion of Investigative Pipeline

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Spotlighted in Recent EIO Report from Crystal Research Associates

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board Member Named to the Order of Canada

QualityStocksNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Participation in Upcoming H.C. Wainwright Bioconnect Conference

Market Basics

Newsletter Publishers

Public Companies